CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

The Potential of Strategic Partnering with CROs

Life Sciences Review | Monday, April 19, 2021
Tweet

Consider the huge costs associated with slow research start-ups, which delay trial completion and, as a result, slow time to mark. These and other clinical development issues necessitate creative solutions, which can and should be provided by strategic alliances between sponsors and CROs.


FREMONT, CA : The pharmaceutical industry has long been known for its strategic partnerships. There are numerous arrangements for in-licensing, out-licensing, joint research, and codevelopment between and among biopharmaceutical companies, as well as with academic research institutions. As per one article, approximately 33% of drugs in the top ten pharmaceutical firms' pipelines were produced elsewhere. According to one survey, over 80 percent of biopharma respondents state their alliance participation has risen in the last five years.


What are the Advantages of Forming Strategic Partnerships with CROs?


There is nothing wrong with using Contract Research Organizations (CROs) to support internal workers during busy times of clinical growth. It is much better to do so with clearly aligned goals on both sides than to call a relationship a partnership without specifying how either side will prosper and what each side will need to contribute to and invest to ensure success.


Simultaneously, arms-length transactional arrangements discourage investment, limiting the opportunity for quality improvement, creativity, and learning with and from CROs. Consider the statistics from one study: At least one amendment is required in more than half of all protocols (with later stage trials having the highest average number of amendments). One-third of all amendments should have been stopped. Each amendment lengthens a clinical trial by about two months and costs 500,000 dollars.


Consider the huge costs associated with slow research start-ups, which delay trial completion and, as a result, slow time to mark. These and other clinical development issues necessitate creative solutions, which can and should be provided by strategic alliances between sponsors and CROs. Indeed, relative to sponsors with the highest incidence of delayed and over budget trials, sponsors with the lowest incidence of delayed and over budget trials were more than four times as likely to say that their CROs had delivered innovation, according to another study. Jointly and concretely established innovation goals, a high level of knowledge sharing, a zeal to invest (time, resources, effort), a tolerance for failure, and a high level of appreciation for different ideas and perspectives were all key enablers of such innovation.


Weekly Brief

loading
Towards a New World Order
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/the-potential-of-strategic-partnering-with-cros-nwid-331.html